Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results from ORBITA-2 | JACC

This week's edition of JACC This Week brings Dr. Carolyn Lam and Dr. Harlan Krumholz into a deep exploration of a special issue devoted to innovative cardiovascular research emerging from China. As they highlight newly published studies and their global significance, they reflect on how scientific progress accelerates when discoveries are shared across regions and cultures. Their conversation reinforces a central message: advancing cardiovascular health requires collective effort, open exchange, and a commitment to evaluating science based on quality—not geography.

Drs. Carolyn Lam and Harlan Krumholz unpack new JACC research on cardiometabolic health, highlighting how COVID‑19 shaped cardiovascular care, mortality patterns, and disparities. They also break down updated evidence on PREVENT risk equations in young adults, gaps in lipid testing and statin use, and what these findings mean for modern cardiovascular prevention and population health. JACC This Week — impactful science with global insights.

In this episode, Dr. Carolyn Lam and Dr. Harlan Krumholz break down key studies from this week's JACC issue, including new evidence on Chagas‑related heart failure, updated diastolic function guidelines, and the connection between cardiomyopathy gene variants and atrial fibrillation. They also discuss findings on racial and ethnic disparities in England's universal health system and reflect on how emerging AI tools could transform cardiovascular care. A concise, insightful look at major advances shaping modern cardiology and global heart‑health practice.

Dr. Carolyn Lam and Dr. Harlan Krumholz sit down with Dr. Rishi Wadhera to unpack the first-ever JACC Cardiovascular Statistics issue. They explore why this annual report matters, the key trends in U.S. cardiovascular health, and what clinicians should take away about hypertension, diabetes, obesity, and heart‑failure patterns. The discussion highlights implementation gaps, disparities, and how data can guide action in heart health.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes? Framed by the Editor's Page, "What Does Improvement Mean?", this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit. Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC's commitment to precision, equity, and innovation. This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight the 2025 Adult Congenital Heart Disease (ACHD) Guidelines and explore what they signal for the future of cardiovascular care. Framed by Dr. Krumholz's Editor's Page, "From Survival to Stewardship," this discussion highlights a broader transformation in cardiology: advances that once turned fatal conditions into survivable ones now demand lifelong, structured, and hyper-specialized care. The conversation examines how ACHD exemplifies the shift from episodic survival to coordinated stewardship—where surveillance, systems design, and scalable expertise are essential. The episode also reviews key updates from the guidelines, including risk-based classification, lifelong monitoring, ACHD center collaboration, and global and early-career perspectives. Additional highlights from the issue include cardiac screening in the young, cardio-renal trial insights from CONFIDENCE, wildfire-related cardiovascular risk, and emerging cardiometabolic intersections. This mini-spotlight issue challenges clinicians to rethink how specialized cardiovascular care can be delivered effectively at scale.

This bonus episode continues the conversation from the JACC Women's Cardiovascular Health Issue, moving from science to systems. In this extended discussion, Drs. Carolyn Lam and Harlan Krumholz are joined by Sarah Krumholz to reflect on how the culture and structure of cardiology shape the experiences of women in training and practice.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz explore the JACC Women's Cardiovascular Health Issue—an edition dedicated to advancing science, care, and professional culture for women in cardiology. The discussion spans original research and viewpoints addressing menopause and cardio-oncology risk, sex differences in dilated cardiomyopathy, device trials, rehabilitation after heart failure, global disparities, and the intersection of sex, race, and socioeconomic status in cardiovascular outcomes. Beyond inclusion, this episode highlights a deeper challenge: whether our systems of evidence generation, clinical care, and professional training are designed to serve women fully and routinely. The conversation also features a powerful viewpoint by Sarah Krumholz, Dueling Pursuits: Balancing Motherhood and Medicine, catalyzing a broader dialogue about leadership gaps, culture, and the future of cardiology. This episode sets the stage for a special bonus continuation focused on redesigning the profession for the next generation.

In this episode of JACC This Week, Dr. Harlan M. Krumholz and Dr. Carolyn S.P. Lam discuss a dedicated issue of JACC focused on cardiac amyloidosis—one of the fastest-evolving areas in cardiovascular medicine. They explore new evidence highlighting significant delays in diagnosing ATTR cardiomyopathy, the early divergence of mortality benefit with timely treatment, and why time to diagnosis is no longer a neutral factor. The conversation also examines secondary analyses from major clinical trials, practical guidance for amyloidosis evaluation and management, and Dr. Krumholz's Editor's Page on "computable diagnosis" as a moral imperative. This episode places emerging science in clinical context, emphasizing urgency, equity, and how clinicians should be thinking differently about diagnosis, staging, and access to therapy in amyloid heart disease. Read Full issue here: https://www.jacc.org/toc/jacc/87/5 Keywords: cardiac amyloidosis, amyloid heart disease, ATTR cardiomyopathy, computable diagnosis

Welcome to the new season of JACC This Week! In this episode, Editor-in-Chief Dr. Harlan Krumholz is joined by co-host Dr. Carolyn Lam to kick off a refreshed, more conversational era of the podcast. Together, they reflect on the evolution of the show, approach to thematic curation, and introduce the February 3 issue of JACC, curated around valve heart disease. The discussion explores JACC's approach to thematic issues, the importance of timely publication, and how emerging evidence is shifting valvular heart disease management toward lifetime decision-making and patient-centered outcomes. Highlights include insights into aortic stenosis and regurgitation, tricuspid regurgitation, global perspectives on valve care, and what clinicians should be watching as transcatheter therapies continue to evolve. Dr. Krumholz also shares the thinking behind his Editor's Page on scientific writing—specifically, how a strong introduction earns the reader's trust—offering practical guidance for researchers at all stages. The episode sets the tone for a new season focused on rigor, relevance, global inclusion, and meaningful dialogue with the cardiovascular community.